Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its senior management ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The logo of French-Austrian biotech firm Valneva is seen outside their headquarters in Vienna, Austria, December 16, ...

The U.S. Food and Drug Administration (FDA) late Friday announced that it has suspended the marketing application granted for French biotech Valneva’s (NASDAQ:VALN) chikungunya vaccine Ixchiq due to ...

If you are wondering whether Valneva is priced attractively right now, it helps to step back and look at what the recent share performance and valuation metrics are really telling you. The stock last ...

The stage is set for a defining period. Valneva's strategic pivot has garnered investor confidence, and its financial runway is secure. All eyes are now on the scientific data expected in the coming ...

Valneva SE (NASDAQ:VALN) stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) suspended the license for Ixchiq, citing four new reports of serious adverse events (SAEs) ...

Valneva SE (NASDAQ: VALN) on Monday said it has decided to voluntarily withdraw the biologics license application (BLA) and Investigational New Drug (IND) application for its chikungunya vaccine, ...

BUY-Empfehlung und senkt das Kursziel von EUR 6,80 auf EUR 6,60. von EUR157,9 Mio. (FBe: EUR155,1 Mio.; 2024: EUR163,3 Mio.) lag am unteren Ende Rückgang der Verkäufe an Dritte um 43,2% auf EUR19,2 ...

Valneva shares rose after the French biotech company reported positive data from a mid-stage study of a Lyme disease vaccine candidate it is developing jointly with Pfizer. Shares in Valneva climbed ...

Valneva (VALN) and the world’s largest vaccine maker, Serum Institute of India, announced on Wednesday that they have mutually agreed to discontinue their licensing agreement for the former’s ...

FILE PHOTO: The logo of French-Austrian biotech firm Valneva is seen outside their headquarters in Vienna, Austria, December 16, 2021. REUTERS/Lisi Niesner/File Photo Jan 19 (Reuters) - French ...

Shares in Valneva rose after the French biotech company reported positive final data from a mid-stage study of a Lyme disease vaccine candidate it is developing with Pfizer. Valneva said that antibody ...